Thank you for writing to us. One of our executive will reach back to you through your submitted medium. In case there’s an urgency, feel free to connect over WhatsApp for faster response.
Prefer calling? Dial +9108048038777 (international callers) or 08048038777 (Indian callers).
Zonex P 50 mg/500 mg Tablet – Description
Zonex P 50 mg/500 mg Tablet is a combination medicine commonly used for the relief of pain and inflammation associated with conditions such as muscle pain, joint pain, back pain, sprains, strains, and other painful musculoskeletal conditions. It contains Diclofenac 50 mg and Paracetamol 500 mg, which work together to provide pain-relieving and anti-inflammatory effects.
Diclofenac helps reduce pain, swelling, and inflammation, while Paracetamol helps relieve pain and fever. The medicine should be taken only as directed by a doctor, preferably with or after food to reduce the risk of stomach discomfort.
Key Uses:
Relief from muscle and joint pain
Back pain and body aches
Pain associated with sprains and strains
Inflammatory conditions
Short-term relief of mild to moderate pain
Ranozex Tablet ER is an extended-release medication containing Ranolazine, commonly used in the management of chronic angina (chest pain caused by reduced blood flow to the heart). It helps improve the heart’s ability to function efficiently and may reduce the frequency of angina episodes.
Ranozex Tablet ER – Key Benefits
Helps manage symptoms of chronic stable angina
May reduce the frequency of chest pain episodes
Supports improved exercise tolerance in eligible patients
Extended-release formulation provides prolonged drug action
How It Works
Ranozex Tablet ER works primarily by affecting sodium-dependent processes in heart muscle cells, helping improve the balance between oxygen supply and demand in the heart and reducing symptoms of chronic angina.
Important Information
Ranozex Tablet ER should be taken only as prescribed by a qualified healthcare professional. The tablet should generally be swallowed whole and not crushed or chewed. It is not intended to treat an acute angina attack.
25 mg Hibose Acarbose Tablets – Description
Hibose 25 mg Acarbose Tablets contain Acarbose 25 mg, an oral antidiabetic medicine used as part of a comprehensive treatment plan for Type 2 diabetes mellitus. Acarbose belongs to the alpha-glucosidase inhibitor class and works mainly in the intestine by slowing the digestion and absorption of carbohydrates, helping reduce the rise in blood glucose levels after meals.
Hibose 25 mg may be prescribed along with a suitable diet and exercise program, either alone or with other diabetes medicines, according to a healthcare professional's advice. It is generally taken with the first bite of a meal, and the dosage is adjusted based on individual blood glucose control and medical guidance.
Key features:
Contains Acarbose 25 mg
Oral tablet formulation
Helps control post-meal blood glucose
Used in the management of Type 2 diabetes
Works by delaying carbohydrate digestion and glucose absorption
Should be used under medical supervision
Important: Hibose 25 mg should be taken only as prescribed. Common digestive side effects may include flatulence, abdominal discomfort, and diarrhea. It is not intended for the treatment of Type 1 diabetes or diabetic ketoacidosis.
50 mg Niddmose Acarbose Tablets – Description
Niddmose 50 mg Acarbose Tablets contain Acarbose 50 mg, an oral antidiabetic medicine used as part of the management of Type 2 diabetes (NIDDM). Acarbose belongs to the alpha-glucosidase inhibitor class and helps control blood glucose levels by slowing the digestion and absorption of carbohydrates in the intestine.
Niddmose 50 mg is generally taken with the first bite of a meal, as directed by a qualified healthcare professional. It may be prescribed alone or together with other diabetes medicines when additional blood glucose control is required.
Key features:
Contains Acarbose 50 mg
Used in the management of Type 2 diabetes
Helps reduce post-meal blood glucose elevation
Works by slowing carbohydrate digestion
Oral tablet formulation
Should be used according to medical advice
Important: This medicine should be used only under the supervision of a healthcare professional. Common gastrointestinal effects may include flatulence, abdominal discomfort, or diarrhea.
Glyxambi 10 mg Empagliflozin + 5 mg Linagliptin Tablets – Description
Glyxambi 10 mg/5 mg Tablets contain a combination of Empagliflozin 10 mg and Linagliptin 5 mg, two oral medicines used to help manage Type 2 diabetes mellitus. Empagliflozin belongs to the SGLT2 inhibitor class and helps the kidneys remove excess glucose through urine, while Linagliptin is a DPP-4 inhibitor that helps improve the body’s natural insulin response after meals.
This combination may be prescribed along with diet and exercise when additional blood-glucose control is needed. Glyxambi is intended for adults with Type 2 diabetes and should be used strictly according to the healthcare professional’s prescription.
Key Features:
Contains Empagliflozin 10 mg + Linagliptin 5 mg
Oral combination therapy for Type 2 diabetes
Helps improve blood-glucose control through complementary mechanisms
Available as convenient tablets
Prescription medicine requiring professional medical guidance
Gabatop NT – Gabapentin Plus Nortriptyline Combination
Gabatop NT is a prescription combination medicine containing Gabapentin and Nortriptyline, commonly used in the management of neuropathic (nerve) pain. Gabapentin helps reduce abnormal nerve activity, while Nortriptyline, a tricyclic antidepressant, can help modulate pain signals in the nervous system.
This combination may be prescribed for conditions such as diabetic nerve pain, post-herpetic neuralgia, sciatica, and other forms of chronic neuropathic pain, depending on a healthcare professional's assessment. It may also help improve sleep disturbances associated with nerve pain.
Key Features:
Combination of Gabapentin and Nortriptyline
Designed for neuropathic pain management
Helps reduce abnormal nerve-related pain signals
May support improved sleep when pain interferes with rest
Available only with appropriate medical guidance
Important: Gabatop NT should be taken only as prescribed. It can cause drowsiness, dizziness, dry mouth, constipation, or blurred vision in some people. Avoid driving or operating machinery until you know how it affects you. Do not stop treatment suddenly without consulting your doctor.
Glycomet GP 2 mg Tablet – Description
Glycomet GP 2 mg is a combination oral antidiabetic medicine containing Metformin Hydrochloride Sustained Release and Glimepiride. It is used along with a suitable diet and regular physical activity to help manage Type 2 diabetes mellitus when lifestyle measures alone are not sufficient.
Metformin Hydrochloride SR helps reduce glucose production by the liver and improves the body's sensitivity to insulin, while Glimepiride helps the pancreas release insulin, supporting better blood-glucose control.
Key Features:
Combination of Metformin Hydrochloride Sustained Release and Glimepiride
Helps control elevated blood glucose levels in Type 2 diabetes
Sustained-release formulation of Metformin
Intended for use under medical supervision
Should be taken according to the prescribed dosage and schedule
Important: This medicine may cause low blood sugar, particularly when meals are skipped or when used with other glucose-lowering medicines. Common side effects may include nausea, diarrhea, stomach discomfort, or headache. It should be used only as directed by a qualified healthcare professional.
Hibose 50 mg Tablet is a pharmaceutical formulation containing Acarbose 50 mg, an oral antidiabetic medicine used to help control blood glucose levels in people with Type 2 diabetes. It works primarily in the digestive tract by slowing the breakdown and absorption of carbohydrates, helping reduce the rise in blood sugar after meals.
Hibose 50 mg is generally taken with the first bite of a meal, as directed by a healthcare professional. It may be prescribed alone or alongside other diabetes medicines when additional blood-glucose control is required.
Key Features:
Contains Acarbose 50 mg
Helps control post-meal blood glucose levels
Used as part of Type 2 diabetes management
Works by delaying carbohydrate digestion and glucose absorption
Should be used according to a doctor's prescription
Important: Hibose 50 mg should be taken only as prescribed. Common side effects may include gas, abdominal discomfort, bloating, or diarrhea, particularly when treatment is started. Consult a healthcare professional for appropriate dosage and use.
Lenakast 10mg Capsule – Product Description
Lenakast 10mg Capsule is a prescription medicine commonly used in the management of allergic conditions, depending on its active ingredient and prescribed indication. It may help relieve symptoms such as sneezing, runny or blocked nose, itching, and watery eyes.
Key Benefits:
Helps manage allergy-related symptoms
May reduce sneezing and nasal irritation
Helps relieve itching and watery eyes
Can support better comfort during allergic episodes
Important: Use Lenakast 10mg Capsule only as directed by a qualified healthcare professional. The exact uses, dosage, precautions, and side effects depend on the medicine's active ingredient and the patient's condition. Avoid self-medication.
Description
Lenangio 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes
Extensive Product Profile: In-Depth Insights on Lenangio 10mg Capsules
Lenangio 10mg Capsule, manufactured under strict global GMP compliance standards within India, is a highly effective mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core.
1. Clinical Indications & Target Therapeutic Applications
Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity.
Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a specific cytogenetic abnormality—the deletion 5q (del 5q) chromosomal mutation, with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib.
2. Comprehensive Mechanism of Action (MOA)
Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation.
Direct Tumor Suppression & Apoptosis: The destruction of Ikaros and Aiolos causes a down-regulation of crucial survival factors in B-cell malignancies, leading to immediate cell cycle arrest and programmed cell death (apoptosis) in malignant plasma cells.
3. Storage, Stability, and Handling Protocols
Environmental Matrix: Store Lenangio 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light.
Administration Matrix: Capsules must be swallowed completely whole with a glass of water, once daily at the same time, either with or without food. Do not crush, chew, open, or break the capsule shell, as direct contact with the internal powder poses handling risks and alters designated absorption rates.
Potential Side Effects of Lenangio 10mg
Severe Myelosuppression: Significant reductions in blood cell counts, leading to severe neutropenia (low white cells increasing susceptibility to infections), thrombocytopenia (low platelets increasing bruising or bleeding hazards), and anemia (causing extreme fatigue and weakness). Regular Complete Blood Counts (CBC) are required before and during treatment.
Venous and Arterial Thromboembolism: Patients treated with Lenalidomide face a significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke. Prophylactic antithrombotic therapy is highly recommended for most patients.
Description
Lenangio 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes
Extensive Product Profile: In-Depth Insights on Lenangio 10mg Capsules
Lenangio 10mg Capsule, manufactured under strict global GMP compliance standards within India, is a highly effective mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core.
1. Clinical Indications & Target Therapeutic Applications
Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity.
Myelodysplastic Syndromes (MDS): Indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with a specific cytogenetic abnormality—the deletion 5q (del 5q) chromosomal mutation, with or without additional cytogenetic abnormalities.
Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib.
2. Comprehensive Mechanism of Action (MOA)
Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation.
Direct Tumor Suppression & Apoptosis: The destruction of Ikaros and Aiolos causes a down-regulation of crucial survival factors in B-cell malignancies, leading to immediate cell cycle arrest and programmed cell death (apoptosis) in malignant plasma cells.
3. Storage, Stability, and Handling Protocols
Environmental Matrix: Store Lenangio 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light.
Description
Lendomy 10mg Capsule: Advanced Immunomodulatory Therapy for Multiple Myeloma and Myelodysplastic Syndromes
Extensive Product Profile: In-Depth Insights on Lendomy 10mg Capsules
Lendomy 10mg Capsule, manufactured under strict global compliance systems within India (by Mylan/Viatris Pharmaceuticals Pvt. Ltd.), is a highly effective mid-range oral antineoplastic and immunomodulatory treatment. Each capsule contains precisely Lenalidomide ($10text{ mg}$) as its active pharmaceutical ingredient. Lenalidomide is a potent analogue of thalidomide belonging to the chemical class of isoindolones. It is designed to selectively manipulate cellular environments, alter cytokine release, and stimulate defense cells to disrupt blood-based cancers at their core.
1. Clinical Indications & Target Therapeutic Applications
Multiple Myeloma (MM): Used in combination with dexamethasone or as a standalone maintenance therapy following autologous stem cell transplantation (ASCT) for patients with newly diagnosed or relapsed/refractory multiple myeloma. The $10text{ mg}$ strength is highly utilized for strategic dose maintenance or during scheduled step-down titration cycles to control drug toxicity.
Mantle Cell Lymphoma (MCL): Prescribed for patients with mantle cell lymphoma whose disease has relapsed or progressed after two prior therapies, one of which must have included bortezomib.
Follicular Lymphoma (FL) & Marginal Zone Lymphoma (MZL): Utilized in combination with rituximab for previously treated adults with follicular or marginal zone lymphomas to control slow-progressing B-cell cancers.
2. Comprehensive Mechanism of Action (MOA)
Cereblon E3 Ubiquitin Ligase Binding: Lenalidomide binds directly to cereblon (CRBN), a component of the cullin-RING E3 ubiquitin ligase enzyme complex. This binding selectively alters the substrate specificity of the ligase, targeting two essential lymphoid transcription factors—IKZF1 (Ikaros) and IKZF3 (Aiolos)—for rapid cellular degradation.
Immune System Modulation: It heavily boosts the body's natural defenses by stimulating T-cells and Natural Killer (NK) cells, increasing their capacity to recognize, attack, and clear out abnormal cancer cells roaming the bone marrow.
3. Storage, Stability, and Handling Protocols
Environmental Matrix: Store Lendomy 10mg Capsules in their original moisture-resistant container or blister packaging at controlled room temperature, strictly below 30°C (86°F). Protect the inventory from high ambient steam, humidity, heat, and direct exposure to light.
Administration Matrix: Capsules must be swallowed completely whole with a glass of water, once daily at the same time, either with or without food. Do not crush, chew, open, or break the capsule shell, as direct contact with the internal powder poses handling risks and alters designated absorption rates.
Potential Side Effects of Lendomy 10mg
Severe Myelosuppression: Significant reductions in blood cell counts, leading to severe neutropenia (low white cells increasing susceptibility to infections), thrombocytopenia (low platelets increasing bruising or bleeding hazards), and anemia (causing extreme fatigue and weakness). Regular Complete Blood Counts (CBC) are required before and during treatment.
Venous and Arterial Thromboembolism: Patients treated with Lenalidomide face a significantly increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke. Prophylactic antithrombotic therapy is highly recommended for most patients.
Export Documentation & Global Trade Compliance
Certificate of Analysis (COA): Providing verifiable batch testing confirming the precise $10text{ mg}$ Lenalidomide strength, active capsule dissolution profiles, and chemical purity indices.